



Patients with low muscle mass experience more dose-limiting toxicities to:

- A. fluorouracil (5-FU) in colon cancer
- B. capecitabine in breast cancer
- C. sorafenib in renal cell carcinoma
- D. 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in breast cancer
- E. sorafenib in hepatocellular carcinoma
- F. sunitinib in renal cell carcinoma
- G. vandetanib in medullary thyroid cancer

- H. fluropyrimidine in colorectal cancer
- I. phase I drugs in mixed cancer types
- J. imatinib in gastrointestinal stromal tumours (grade I-II toxicity)
- K. Epirubicin, cisplatin, capecitabine (ECX) and cisplatin, 5-fluorouracil (CF) in oesophagogastric cancer
- L. taxane-based chemotherapy (placitaxel, docetaxel, nab-paclitaxel) in breast cancer
- M. hyperthermic intraperitoneal chemotherapy (oxaliplatin and irinotecan) in colorectal cancer
- N. neoadjuvant chemotherapy (NACT) (mixed types) in gastric cancer
- O. ipilimumab in metastatic melanoma

Percentages shown are representative findings of individual studies summarised in Daly et al, not a pooled meta-analysis estimate.

Reference: Daly LE, et al. Proc Nutr Soc. 2018;77(2):135-151.